<?xml version="1.0" encoding="utf-8"?>
<feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom">
  <title
    type="text">InMed Pharmaceuticals Inc.</title>
  <subtitle
    type="text">Contains the last 20 releases</subtitle>
  <id>uuid:9c178412-5e1e-4b1d-8a94-cdc24deb24d6;id=2510</id>
  <rights
    type="text">Copyright 2023, InMed Pharmaceuticals Inc.</rights>
  <updated>2023-02-17T22:00:00Z</updated>
  <author>
    <name>newsdesk@globenewswire.com (NewsDesk)</name>
    <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri>
    <email>newsdesk@globenewswire.com</email>
  </author>
  <link
    rel="alternate"
    href="https://www.globenewswire.com/atomfeed/organization/yZz9WuFxee1efD0z4T4dgw==" />
  <link
    rel="self"
    href="https://www.globenewswire.com/atomfeed/organization/yZz9WuFxee1efD0z4T4dgw==" />
  <entry>
    <id>https://www.globenewswire.com/news-release/2023/02/17/2610993/36215/en/InMed-Reports-Second-Quarter-Fiscal-2023-Financial-Results-and-Provides-Business-Update.html</id>
    <title
      type="text">InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update</title>
    <published>2023-02-17T22:00:00Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2023/02/17/2610993/36215/en/InMed-Reports-Second-Quarter-Fiscal-2023-Financial-Results-and-Provides-Business-Update.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Feb.  17, 2023  (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“<strong>InMed</strong>” or the “<strong>Company</strong>”) (<strong>Nasdaq: INM</strong>), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced financial results for the second quarter of fiscal year 2023 which ended December 31, 2022.</p>]]></content>
    <dc:identifier>2610993</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Fri, 17 Feb 2023 22:00 GMT</dc:modified>
    <dc:subject>Earnings Releases and Operating Results</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2023/02/10/2605621/36215/en/InMed-Submits-Form-12b-25.html</id>
    <title
      type="text">InMed Submits Form 12b-25</title>
    <published>2023-02-10T02:41:00Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2023/02/10/2605621/36215/en/InMed-Submits-Form-12b-25.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Feb.  09, 2023  (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“<strong>InMed</strong>” or the “<strong>Company</strong>”) (<strong>Nasdaq: INM</strong>), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces it has submitted a Form 12b-25 with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its Quarterly Report on Form 10-Q for the period ended December 31, 2022 (the “Form 10-Q”).<br></p>]]></content>
    <dc:identifier>2605621</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Fri, 10 Feb 2023 02:41 GMT</dc:modified>
    <dc:subject>Research Analysis and Reports</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2023/01/10/2586035/36215/en/InMed-Provides-Business-Update-and-Milestones-for-2023.html</id>
    <title
      type="text">InMed Provides Business Update and Milestones for 2023</title>
    <published>2023-01-10T12:30:00Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2023/01/10/2586035/36215/en/InMed-Provides-Business-Update-and-Milestones-for-2023.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Jan.  10, 2023  (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“<strong>InMed</strong>” or the “<strong>Company</strong>”) (<strong>Nasdaq: INM</strong>), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today outlines key accomplishments from 2022 and provides business update and catalysts for 2023.</p>]]></content>
    <dc:identifier>2586035</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Tue, 10 Jan 2023 12:30 GMT</dc:modified>
    <dc:subject>Product / Services Announcement</dc:subject>
    <dc:keyword>#INM</dc:keyword>
    <dc:keyword>#rarecannabinoids</dc:keyword>
    <dc:keyword>$INM</dc:keyword>
    <dc:keyword>biotech</dc:keyword>
    <dc:keyword>cannabinoids</dc:keyword>
    <dc:keyword>clinical trial</dc:keyword>
    <dc:keyword>Phase 2</dc:keyword>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/12/15/2575160/36215/en/InMed-Announces-Results-of-2022-Annual-General-Meeting.html</id>
    <title
      type="text">InMed Announces Results of 2022 Annual General Meeting</title>
    <published>2022-12-15T23:17:51Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/12/15/2575160/36215/en/InMed-Announces-Results-of-2022-Annual-General-Meeting.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Dec.  15, 2022  (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“<strong>InMed</strong>” or the “<strong>Company</strong>”) (<strong>Nasdaq: INM</strong>), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today confirmed that, at its annual general meeting of shareholders held on December 15, 2022 (the “Meeting”), all of the matters put forward before shareholders for consideration and approval as set out in InMed’s notice of meeting and management information circular, dated October 28, 2022, were approved by the shareholders. In particular, shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Results of the vote for the election of directors at the Meeting are set out as follows:</p>]]></content>
    <dc:identifier>2575160</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Thu, 15 Dec 2022 23:18 GMT</dc:modified>
    <dc:subject>Annual Meetings &amp; Shareholder Rights</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/12/12/2572311/36215/en/InMed-Announces-Appointment-of-Interim-Chief-Financial-Officer-and-Change-of-Auditor.html</id>
    <title
      type="text">InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor</title>
    <published>2022-12-12T23:47:40Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/12/12/2572311/36215/en/InMed-Announces-Appointment-of-Interim-Chief-Financial-Officer-and-Change-of-Auditor.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Dec.  12, 2022  (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“<strong>InMed</strong>” or the “<strong>Company</strong>”) (<strong>Nasdaq: INM</strong>), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces the Company has entered into a service contract (the “Contract”) with Brio Financial Group (“Brio”) to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022.<br></p>]]></content>
    <dc:identifier>2572311</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Mon, 12 Dec 2022 23:48 GMT</dc:modified>
    <dc:subject>Directors and Officers</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/11/21/2560350/36215/en/InMed-Pharmaceuticals-Announces-Closing-of-6-Million-Private-Placement-Priced-at-a-Premium-to-Market.html</id>
    <title
      type="text">InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market</title>
    <published>2022-11-21T22:00:00Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/11/21/2560350/36215/en/InMed-Pharmaceuticals-Announces-Closing-of-6-Million-Private-Placement-Priced-at-a-Premium-to-Market.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Nov.  21, 2022  (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“<strong>InMed</strong>” or the “<strong>Company</strong>”) (<strong>Nasdaq: INM</strong>), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced the closing of its previously announced private placement with two healthcare-focused institutional investors for the issuance and sale of 1,818,185 of its common shares at a purchase price of $3.30 per share (or pre-funded warrant in lieu thereof) priced at-the-market under Nasdaq rules. In addition, the Company has issued to the investors in the offering unregistered preferred investment options (the “investment options”) to purchase up to an aggregate of 3,272,733 common shares. The aggregate gross proceeds to the Company from the private placement were approximately $6 million. The Company intends to use the net proceeds from the offering to continue pipeline development of its pharmaceutical drug candidates, advance manufacturing know-how of cannabinoids and cannabinoid analogs, support intellectual property development and other commercial activities, and for general working capital purposes.</p>]]></content>
    <dc:identifier>2560350</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Mon, 21 Nov 2022 22:00 GMT</dc:modified>
    <dc:subject>Major shareholder announcements</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/11/18/2559080/36215/en/InMed-Pharmaceuticals-Announces-6-Million-Private-Placement-Priced-at-a-Premium-to-Market.html</id>
    <title
      type="text">InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market</title>
    <published>2022-11-18T13:00:00Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/11/18/2559080/36215/en/InMed-Pharmaceuticals-Announces-6-Million-Private-Placement-Priced-at-a-Premium-to-Market.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Nov.  18, 2022  (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“<strong>InMed</strong>” or the “<strong>Company</strong>”) (<strong>Nasdaq: INM</strong>), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced that it has entered into a securities purchase agreement with two healthcare-focused institutional investors for the issuance and sale of 1,818,185 of its common shares at a purchase price of $3.30 per share (or pre-funded warrant in lieu thereof) in a private placement priced at-the-market under Nasdaq rules. In addition, the Company has agreed to issue to the investors in the offering unregistered preferred investment options (the “investment options”) to purchase up to an aggregate of 3,272,733 common shares. The aggregate gross proceeds to the Company from the private placement is expected to be approximately $6 million. The offering is expected to close on or about November 21, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to continue pipeline development of its pharmaceutical drug candidates, advance manufacturing know-how of cannabinoids and cannabinoid analogs, support intellectual property development and other commercial activities, and for general working capital purposes.<br></p>]]></content>
    <dc:identifier>2559080</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Fri, 18 Nov 2022 13:00 GMT</dc:modified>
    <dc:subject>Changes in company's own shares</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/11/17/2558082/36215/en/InMed-Provides-Update-on-Management-Changes.html</id>
    <title
      type="text">InMed Provides Update on Management Changes</title>
    <published>2022-11-17T12:30:00Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/11/17/2558082/36215/en/InMed-Provides-Update-on-Management-Changes.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Nov.  17, 2022  (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces that Sarah Li has been promoted to Vice President of Accounting and Controller at InMed. Ms. Brenda Edwards will be transitioning out of her position as interim Chief Financial Officer at the Company effective November 20, 2022.  Ms. Edwards joined the Company in an interim contract role to assist the Company with financial reporting matters following the retirement of the Company’s former Chief Financial Officer in March 2022.<br></p>]]></content>
    <dc:identifier>2558082</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Thu, 17 Nov 2022 12:30 GMT</dc:modified>
    <dc:subject>Directors and Officers</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/11/16/2557041/36215/en/InMed-Pharmaceuticals-Advances-Neurodegenerative-Disease-Program-with-Natural-Sciences-and-Engineering-Research-Council-of-Canada-NSERC-Alliance-Grant-Funding.html</id>
    <title
      type="text">InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding</title>
    <published>2022-11-16T12:00:00Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/11/16/2557041/36215/en/InMed-Pharmaceuticals-Advances-Neurodegenerative-Disease-Program-with-Natural-Sciences-and-Engineering-Research-Council-of-Canada-NSERC-Alliance-Grant-Funding.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Nov.  16, 2022  (GLOBE NEWSWIRE) -- <strong>InMed Pharmaceuticals Inc.</strong> (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces the launch of its neurodegenerative disease program (INM-900 series), which will be investigating the effects of cannabinoid analogs in diseases such as Alzheimer’s, Huntington’s and Parkinson’s.</p>]]></content>
    <dc:identifier>2557041</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Wed, 16 Nov 2022 12:01 GMT</dc:modified>
    <dc:subject>Clinical Study</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/11/11/2554425/36215/en/InMed-Pharmaceuticals-Reports-First-Quarter-Fiscal-2023-Financial-Results-and-Provides-Business-Update.html</id>
    <title
      type="text">InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update</title>
    <published>2022-11-11T23:51:30Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/11/11/2554425/36215/en/InMed-Pharmaceuticals-Reports-First-Quarter-Fiscal-2023-Financial-Results-and-Provides-Business-Update.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Nov.  11, 2022  (GLOBE NEWSWIRE) -- <strong>InMed Pharmaceuticals Inc.</strong> (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the first quarter of fiscal year 2023, ended September 30, 2022.<br></p>]]></content>
    <dc:identifier>2554425</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Fri, 11 Nov 2022 23:51 GMT</dc:modified>
    <dc:subject>Earnings Releases and Operating Results</dc:subject>
    <dc:subject>Health</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/11/10/2553080/36215/en/Registration-Now-Open-For-Tribe-Public-s-Webinar-Event-Exploring-the-Neuroprotective-Qualities-of-Rare-Cannabinoids-Featuring-InMed-s-Management-Team-On-November-17-2022.html</id>
    <title
      type="text">Registration Now Open For Tribe Public’s Webinar Event  "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed’s Management Team On November 17, 2022</title>
    <published>2022-11-10T12:30:00Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/11/10/2553080/36215/en/Registration-Now-Open-For-Tribe-Public-s-Webinar-Event-Exploring-the-Neuroprotective-Qualities-of-Rare-Cannabinoids-Featuring-InMed-s-Management-Team-On-November-17-2022.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[Meet with InMed’s President and CEO Eric A. Adams and Eric Hsu, SVP of Preclinical Research and Development <pre>Meet with InMed’s President and CEO Eric A. Adams and Eric Hsu, SVP of Preclinical Research and Development</pre>]]></content>
    <dc:identifier>2553080</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Thu, 10 Nov 2022 12:31 GMT</dc:modified>
    <media:content
      medium="image"
      type="image/jpeg"
      width="600"
      url="https://ml.globenewswire.com/Resource/Download/4e763182-a187-46c7-bb33-93871280de8f">
      <media:text
        type="html"><![CDATA[<p>
  <a href="https://www.globenewswire.com/news-release/2022/11/10/2553080/36215/en/Registration-Now-Open-For-Tribe-Public-s-Webinar-Event-Exploring-the-Neuroprotective-Qualities-of-Rare-Cannabinoids-Featuring-InMed-s-Management-Team-On-November-17-2022.html">
    <img src="https://ml.globenewswire.com/Resource/Download/4e763182-a187-46c7-bb33-93871280de8f" width="600" align="left" border="0" alt="Tribe Webinar InMed Nov 17 2022" title="Tribe Webinar - InMed November 17, 2022" />
  </a>
</p><br clear="all" />]]></media:text>
      <media:credit
        role="publishing company">GlobeNewswire Inc.</media:credit>
    </media:content>
    <dc:subject>Company Announcement</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/10/26/2541688/36215/en/InMed-Pharmaceuticals-Supports-Epidermolysis-Bullosa-Awareness-Week.html</id>
    <title
      type="text">InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week</title>
    <published>2022-10-26T11:30:00Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/10/26/2541688/36215/en/InMed-Pharmaceuticals-Supports-Epidermolysis-Bullosa-Awareness-Week.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Oct.  26, 2022  (GLOBE NEWSWIRE) -- <strong>InMed Pharmaceuticals Inc.</strong> (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, announces it is supporting initiatives to raise awareness of epidermolysis bullosa, a group of rare genetic connective tissue disorders. Epidermolysis Bullosa Global Awareness Week is October 25-31, 2022.<br></p>]]></content>
    <dc:identifier>2541688</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Wed, 26 Oct 2022 11:30 GMT</dc:modified>
    <dc:subject>Calendar of Events</dc:subject>
    <dc:subject>Health</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/09/23/2521998/36215/en/InMed-Pharmaceuticals-Reports-Full-Year-Fiscal-2022-Financial-Results-and-Provides-Business-Update.html</id>
    <title
      type="text">InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update</title>
    <published>2022-09-23T16:29:14Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/09/23/2521998/36215/en/InMed-Pharmaceuticals-Reports-Full-Year-Fiscal-2022-Financial-Results-and-Provides-Business-Update.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Sept.  23, 2022  (GLOBE NEWSWIRE) -- <strong>InMed Pharmaceuticals Inc.</strong> (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022.<br></p>]]></content>
    <dc:identifier>2521998</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Fri, 23 Sep 2022 16:29 GMT</dc:modified>
    <dc:subject>Earnings Releases and Operating Results</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/09/19/2518758/36215/en/InMed-Pharmaceuticals-to-Report-Full-Year-Fiscal-2022-Financial-Results-and-Business-Update-on-September-23-2022.html</id>
    <title
      type="text">InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022</title>
    <published>2022-09-19T22:00:00Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/09/19/2518758/36215/en/InMed-Pharmaceuticals-to-Report-Full-Year-Fiscal-2022-Financial-Results-and-Business-Update-on-September-23-2022.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Sept.  19, 2022  (GLOBE NEWSWIRE) -- <strong>InMed Pharmaceuticals Inc.</strong> (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022.<br></p>]]></content>
    <dc:identifier>2518758</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Mon, 19 Sep 2022 22:00 GMT</dc:modified>
    <dc:subject>Conference Calls/ Webcasts</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/09/13/2515517/36215/en/InMed-Pharmaceuticals-Announces-Closing-of-6-Million-Private-Placement-Priced-at-a-Premium-to-Market.html</id>
    <title
      type="text">InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market</title>
    <published>2022-09-13T21:12:50Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/09/13/2515517/36215/en/InMed-Pharmaceuticals-Announces-Closing-of-6-Million-Private-Placement-Priced-at-a-Premium-to-Market.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Sept.  13, 2022  (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“<strong>InMed</strong>” or the “<strong>Company</strong>”) (<strong>Nasdaq: INM</strong>), a leader in the research, development and manufacturing of rare cannabinoids, today announced the closing of its previously announced private placement with two healthcare-focused institutional investors for the issuance and sale of 691,245 of its common shares at a purchase price of $8.68 per share (or pre-funded warrant in lieu thereof) priced at-the-market under Nasdaq rules. In addition, the Company has issued to the investors in the offering unregistered preferred investment options (the “investment options”) to purchase up to an aggregate of 1,382,490 common shares.<br></p>]]></content>
    <dc:identifier>2515517</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Tue, 13 Sep 2022 21:13 GMT</dc:modified>
    <dc:subject>Stock Market News</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/09/09/2513509/36215/en/InMed-Pharmaceuticals-Announces-6-Million-Private-Placement-Priced-at-a-Premium-to-Market.html</id>
    <title
      type="text">InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market</title>
    <published>2022-09-09T21:00:00Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/09/09/2513509/36215/en/InMed-Pharmaceuticals-Announces-6-Million-Private-Placement-Priced-at-a-Premium-to-Market.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Sept.  09, 2022  (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“<strong>InMed</strong>” or the “<strong>Company</strong>”) (<strong>Nasdaq: INM</strong>), a leader in the research, development and manufacturing of rare cannabinoids, today announced that it has entered into a securities purchase agreement with two healthcare-focused institutional investors for the issuance and sale of 691,245 of its common shares at a purchase price of $8.68 per share (or pre-funded warrant in lieu thereof) in a private placement priced at-the-market under Nasdaq rules. In addition, the Company has agreed to issue to the investors in the offering unregistered preferred investment options (the “investment options”) to purchase up to an aggregate of 1,382,490 common shares. The aggregate gross proceeds to the Company from the private placement is expected to be approximately $6 million. The offering is expected to close on or about September 13, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to continue pipeline development of its pharmaceutical drug candidates, advance manufacturing know-how of cannabinoids and cannabinoid analogs, support intellectual property development and other commercial activities, and for general working capital purposes.</p>]]></content>
    <dc:identifier>2513509</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Fri, 09 Sep 2022 21:00 GMT</dc:modified>
    <dc:subject>Financing Agreements</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/09/08/2512887/36215/en/InMed-Pharmaceuticals-Provides-Update-on-its-Core-Research-and-Development-Programs-and-BayMedica-Business.html</id>
    <title
      type="text">InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business</title>
    <published>2022-09-08T18:08:30Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/09/08/2512887/36215/en/InMed-Pharmaceuticals-Provides-Update-on-its-Core-Research-and-Development-Programs-and-BayMedica-Business.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Sept.  08, 2022  (GLOBE NEWSWIRE) -- <strong>InMed Pharmaceuticals Inc.</strong> (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces an update on its research/development and commercial activities.<br></p>]]></content>
    <dc:identifier>2512887</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Thu, 08 Sep 2022 18:09 GMT</dc:modified>
    <dc:subject>Health</dc:subject>
    <dc:subject>Pre-Release Comments</dc:subject>
    <dc:subject>Restructuring / Recapitalization</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/08/23/2503394/36215/en/InMed-Announces-Share-Consolidation-to-Meet-Nasdaq-Listing-Criteria.html</id>
    <title
      type="text">InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria</title>
    <published>2022-08-23T21:00:00Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/08/23/2503394/36215/en/InMed-Announces-Share-Consolidation-to-Meet-Nasdaq-Listing-Criteria.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Aug.  23, 2022  (GLOBE NEWSWIRE) -- <strong>InMed Pharmaceuticals Inc.</strong> (“<strong>InMed</strong>” or the “<strong>Company</strong>”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces, pursuant to a directors’ resolution, InMed will be consolidating all of its issued and outstanding share capital on the basis of one (1) post‐consolidation share for each twenty five (25) pre‐consolidation common shares of the Company (the “<strong>Consolidation</strong>”) in order to regain compliance with all of Nasdaq’s continued listing requirements.</p>]]></content>
    <dc:identifier>2503394</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Tue, 23 Aug 2022 21:00 GMT</dc:modified>
    <dc:subject>Major shareholder announcements</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/08/09/2494744/36215/en/InMed-Announces-Changes-to-its-Board-of-Directors.html</id>
    <title
      type="text">InMed Announces Changes to its Board of Directors</title>
    <published>2022-08-09T11:30:00Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/08/09/2494744/36215/en/InMed-Announces-Changes-to-its-Board-of-Directors.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Aug.  09, 2022  (GLOBE NEWSWIRE) -- <strong>InMed Pharmaceuticals Inc.</strong> (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately.</p>]]></content>
    <dc:identifier>2494744</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Tue, 09 Aug 2022 11:30 GMT</dc:modified>
    <dc:subject>Directors and Officers</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2022/07/25/2484970/36215/en/InMed-Announces-Update-on-Phase-2-Clinical-Trial-Investigating-INM-755-Cannabinol-Cream-for-Epidermolysis-Bullosa.html</id>
    <title
      type="text">InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa</title>
    <published>2022-07-25T11:30:00Z</published>
    <updated>2024-12-15T03:21:47Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2022/07/25/2484970/36215/en/InMed-Announces-Update-on-Phase-2-Clinical-Trial-Investigating-INM-755-Cannabinol-Cream-for-Epidermolysis-Bullosa.html" />
    <category
      term="Nasdaq:INM"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="CA4576376012"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, July  25, 2022  (GLOBE NEWSWIRE) -- <strong>InMed Pharmaceuticals Inc.</strong> (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today provided an update on its Phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”).</p>]]></content>
    <dc:identifier>2484970</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>InMed Pharmaceuticals Inc.</dc:contributor>
    <dc:modified>Mon, 25 Jul 2022 11:30 GMT</dc:modified>
    <dc:subject>Health</dc:subject>
    <dc:subject>Research Analysis and Reports</dc:subject>
    <dc:keyword>#INM</dc:keyword>
    <dc:keyword>#rarecannabinoids</dc:keyword>
    <dc:keyword>#INMED</dc:keyword>
    <dc:keyword>Epidermolysis Bullosa</dc:keyword>
  </entry>
</feed>